173 related articles for article (PubMed ID: 34510770)
21. Combination of ultrasound and molecular testing in malignancy risk estimate of Bethesda category IV thyroid nodules: results from a single-institution prospective study.
Marina M; Zatelli MC; Goldoni M; Del Rio P; Corcione L; Martorana D; Percesepe A; Bonatti F; Mozzoni P; Crociara A; Ceresini G
J Endocrinol Invest; 2021 Dec; 44(12):2635-2643. PubMed ID: 33860907
[TBL] [Abstract][Full Text] [Related]
22. The McGill Thyroid Nodule Score's (MTNS+) role in the investigation of thyroid nodules with benign ultrasound guided fine needle aspiration biopsies: a retrospective review.
Khalife S; Bouhabel S; Forest VI; Hier MP; Rochon L; Tamilia M; Payne RJ
J Otolaryngol Head Neck Surg; 2016 May; 45(1):29. PubMed ID: 27142264
[TBL] [Abstract][Full Text] [Related]
23. ThyroSeq
Rivas AM; Nassar A; Zhang J; Casler JD; Chindris AM; Smallridge R; Bernet V
Endocr Pract; 2018 Sep; 24(9):780-788. PubMed ID: 30084677
[TBL] [Abstract][Full Text] [Related]
24. Impact of Afirma gene expression classifier on cytopathology diagnosis and rate of thyroidectomy.
Sacks WL; Bose S; Zumsteg ZS; Wong R; Shiao SL; Braunstein GD; Ho AS
Cancer Cytopathol; 2016 Oct; 124(10):722-728. PubMed ID: 27347838
[TBL] [Abstract][Full Text] [Related]
25. Heterogeneity in Positive Predictive Value of RAS Mutations in Cytologically Indeterminate Thyroid Nodules.
Nabhan F; Porter K; Lupo MA; Randolph GW; Patel KN; Kloos RT
Thyroid; 2018 Jun; 28(6):729-738. PubMed ID: 29665745
[TBL] [Abstract][Full Text] [Related]
26. Trends in the Surgical Management of Known or Suspected Differentiated Thyroid Cancer at a Single Institution, 2010-2018.
Zhu CY; Sha SW; Tseng CH; Yang SE; Orr LE; Levin M; Wong CW; Livhits MJ; Rao J; Yeh MW
Thyroid; 2020 Nov; 30(11):1639-1645. PubMed ID: 32515290
[No Abstract] [Full Text] [Related]
27. Risk stratification of the thyroid nodule with Bethesda indeterminate cytology, category III, IV, V on the one surgeon-performed US-guided fine-needle aspiration with 27-gauge needle, verified by histopathology of thyroidectomy: the additional value of one surgeon-performed elastography.
Sengul D; Sengul I; Van Slycke S
Acta Chir Belg; 2019 Feb; 119(1):38-46. PubMed ID: 30606092
[TBL] [Abstract][Full Text] [Related]
28. Fine needle aspiration of the thyroid: correlation with final histopathology in a surgical series of 797 patients.
Lew JI; Snyder RA; Sanchez YM; Solorzano CC
J Am Coll Surg; 2011 Jul; 213(1):188-94; discussion 194-5. PubMed ID: 21601489
[TBL] [Abstract][Full Text] [Related]
29. Effectiveness of Molecular Testing Techniques for Diagnosis of Indeterminate Thyroid Nodules: A Randomized Clinical Trial.
Livhits MJ; Zhu CY; Kuo EJ; Nguyen DT; Kim J; Tseng CH; Leung AM; Rao J; Levin M; Douek ML; Beckett KR; Cheung DS; Gofnung YA; Smooke-Praw S; Yeh MW
JAMA Oncol; 2021 Jan; 7(1):70-77. PubMed ID: 33300952
[TBL] [Abstract][Full Text] [Related]
30. Targeted Next Generation Sequencing with ThyroSeq v2.1 for Indeterminate Thyroid Nodules in Clinical Practice.
Witt RL
Del Med J; 2016 Dec; 88(12):366-372. PubMed ID: 29461717
[TBL] [Abstract][Full Text] [Related]
31. Utility of BRAF mutation detection in fine-needle aspiration biopsy samples read as "suspicious for papillary thyroid carcinoma".
Jara SM; Bhatnagar R; Guan H; Gocke CD; Ali SZ; Tufano RP
Head Neck; 2015 Dec; 37(12):1788-93. PubMed ID: 24989827
[TBL] [Abstract][Full Text] [Related]
32. Risk factors associated with malignancy and with triage to surgery in thyroid nodules classified as Bethesda category III (AUS/FLUS).
Kuru B; Atmaca A; Tarim IA; Kefeli M; Topgul K; Yoruker S; Elmali M; Danaci M
Eur J Surg Oncol; 2016 Jan; 42(1):87-93. PubMed ID: 26527545
[TBL] [Abstract][Full Text] [Related]
33. Bethesda Category III, IV, and V Thyroid Nodules: Can Nodule Size Help Predict Malignancy?
Kiernan CM; Solórzano CC
J Am Coll Surg; 2017 Jul; 225(1):77-82. PubMed ID: 28223197
[TBL] [Abstract][Full Text] [Related]
34. Utilities of
Guan H; Toraldo G; Cerda S; Godley FA; Rao SR; McAneny D; Doherty G; Braverman L; Lee SL
Thyroid; 2020 Apr; 30(4):536-547. PubMed ID: 31996097
[No Abstract] [Full Text] [Related]
35. Analytic and clinical validity of thyroid nodule mutational profiling using droplet digital polymerase chain reaction.
Biron VL; Matkin A; Kostiuk M; Williams J; Cote DW; Harris J; Seikaly H; O'Connell DA
J Otolaryngol Head Neck Surg; 2018 Sep; 47(1):60. PubMed ID: 30249281
[TBL] [Abstract][Full Text] [Related]
36. Ultrasonographic predictors of thyroid cancer in Bethesda III and IV thyroid nodules.
Alyusuf EY; Alhmayin L; Albasri E; Enani J; Altuwaijri H; Alsomali N; Arafah MA; Alyusuf Z; Jammah AA; Ekhzaimy AA; Alzahrani AS
Front Endocrinol (Lausanne); 2024; 15():1326134. PubMed ID: 38405143
[TBL] [Abstract][Full Text] [Related]
37. Positive Correlation of Thyroid Nodule Cytology with Molecular Profiling-a Single-Center Experience.
Tessler I; Shochat I; Cohen O; Meir A; Avior G
Endocr Pathol; 2021 Dec; 32(4):480-488. PubMed ID: 34086262
[TBL] [Abstract][Full Text] [Related]
38. Malignancy outcomes and the impact of repeat fine needle aspiration of thyroid nodules with Bethesda category III cytology: A multicenter experience.
Köseoğlu D; Özdemir Başer Ö; Çetin Z
Diagn Cytopathol; 2021 Oct; 49(10):1110-1115. PubMed ID: 34196509
[TBL] [Abstract][Full Text] [Related]
39. Afirma Gene Sequencing Classifier Compared with Gene Expression Classifier in Indeterminate Thyroid Nodules.
Endo M; Nabhan F; Porter K; Roll K; Shirley LA; Azaryan I; Tonkovich D; Perlick J; Ryan LE; Khawaja R; Meng S; Phay JE; Ringel MD; Sipos JA
Thyroid; 2019 Aug; 29(8):1115-1124. PubMed ID: 31154940
[No Abstract] [Full Text] [Related]
40. Evaluation of BRAF, RAS, RET/PTC, and PAX8/PPARg alterations in different Bethesda diagnostic categories: A multicentric prospective study on the validity of the 7-gene panel test in 1172 thyroid FNAs deriving from different hospitals in South Italy.
Bellevicine C; Migliatico I; Sgariglia R; Nacchio M; Vigliar E; Pisapia P; Iaccarino A; Bruzzese D; Fonderico F; Salvatore D; Biondi B; Masone S; Novizio V; Scavuzzo F; Serino D; De Palma M; Chiofalo MG; Botti G; Pezzullo L; Nuzzo V; Spiezia S; De Chiara G; Iorio S; Conzo G; Docimo G; Faggiano A; Bongiovanni M; Malapelle U; Colao A; Triassi M; Troncone G;
Cancer Cytopathol; 2020 Feb; 128(2):107-118. PubMed ID: 31821746
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
